COVID D/MTA Agreement Signatory Partners*

• Queens University at Kingston
• Research St. Joseph's - Hamilton (RSJ-H)
• Sinai Health System (SHS) (formerly Mount Sinai Hospital (MSH))
• Sunnybrook Research Institute (SRI)
• The Hospital for Sick Children (SickKids)
• Thunder Bay Regional Health Sciences Centre (TBRHSC)
• Trillium Health Partners
• Unity Health Toronto (comprised of Providence Healthcare, St. Joseph's Health Centre and St. Michael's Hospital)
University Health Network (UHN)
• University of Guelph
• University of New Brunswick
• University of Ottawa
• University of Toronto (UofT)
• University of Waterloo
• University of Western Ontario, London
• University of Windsor
• Vitalite Health Network (New Brunswick Regional Health Authority)
• William Osler Health System
• Women's College Hospital
• York University (data only)

• Baycrest Health Sciences (Baycrest Centre for Geriatric Care, Baycrest Hospital, The Baycrest Day Care Centre, The Jewish Home for the Aged)
• Carleton University
• Centre for Addiction & Mental Health (CAMH)
• Hamilton Health Sciences Corporation
• Holland Bloorview Kids Rehabilitation Hospital (HBK)
• Kingston Health Sciences Centre
• Laurentian University
• Lawson Health Research Institute
• McMaster University
• Michael Garron Hospital, Toronto East Health Network
• Montfort Hospital
• North York General Hospital
• Oak Valley Health (comprised of Markham Stouffville Hospital and Uxbridge Hospital) – signatures pending
• Ontario Agency for Health and Promotion (Public Health Ontario)
• Ontario Institute for Cancer Research (OICR)
• Ottawa Hospital Research Institute (OHRI)
• Ontario Tech University
• Provincial Health Services Authority BC
• BC Cancer, BC Centre for Disease Control, and BC Children’s and Women’s Hospital

illustration of two hands shaking


By invitation only

October 10th 2024

MaRs Discovery District, Downtown Toronto

Inaugural in 2024, this exclusive event will bring together  life science industry leaders and investors to learn about the latest initiatives, resources,  innovations and partnership opportunities within Canada’s leading research hospital and medical commercialization centre – University Health Network.

Available by invitation only, this showcase will introduce UHN's new Accelerator Fund and will feature commercially viable and investment-ready life science opportunities from our hospitals and research institutes.

Event Highlights

  • Introduction of the  Accelerator Fund –  
    a premier avenue to advance leading life science discoveries to patient impact
  • Presentation of investment-ready life science opportunities
  • Presentations featuring UHN companies and new ventures
  • Overview of UHN's vast capacity and resources for product development partnerships
  • Keynote Speakers:
    Dr. Scott Bratman: Adela - A Commercialization Journey
    Julie Quenneville and Dr. Miyo Yamashita: Harnessing Venture Philanthropy at UHN
     - Moderated by: Sean Silcoff, Technology Reporter, Globe & Mail

What to Expect

Hear the latest developments directly from our researchers and spin-out companies, which are leading the charge of cutting-edge biomedical discoveries with potential to change patients' lives. You’ll also hear about the leading resources and expertise that UHN can deploy for risk-sharing partnerships.

Keynote Speakers

Dr. Scott Bratman

(MD, PHD), Senior Scientist, Princess Margaret Cancer Centre and Chief Innovation Officer, Adela Inc.
Dr. Scott Bratman is a physician-scientist who is known for his innovative work of developing novel liquid biopsy methods with immense clinical impact. After graduating with a BA in Molecular Biology from Princeton University and a MD/PhD from Columbia University, Bratman conducted a groundbreaking postdoctoral research at Stanford University that advanced the practice of mutation detection within cell-free DNA. Bratman has been able to continue to produce fundamental discoveries in cell-free DNA biology, technologies, and applications as a Principal Investigator at the University of Toronto and Princess Margaret Cancer Centre. As the Chief Innovation Officer at Adela, Dr. Scott Bratman strives to help Adela develop the best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests. Their mission is to deliver innovative and accessible blood tests that harness biology to transform cancer care and improve well-being.

Julie Quenneville

CEO, UHN Foundation
Julie joined the UHN Foundation in March of 2023. She began her career as a journalist before transitioning to a decorated career in the healthcare sector. She served as Associate Chief of Staff to the Quebec Minister of Health before joining McGill University Health Centre (MUHC), where she worked in a number of roles before becoming CEO of MUHC Foundation in 2015. In 2023, Quenneville became CEO of UHN Foundation, where she joins the #1 hospital in Canada in its mission to change the status quo of healthcare. Quenneville has been named one of Canada’s Most Powerful Women, one of Concordia University’s Top 50 under 50, winner of the Women We Admire Award in 2023, and receiving the Medal of the Quebec National Assembly. She has served as Chair of the Banff Forum and is a member of the Executive Committee of the 2024 President’s Cup.

Dr.  Miyo Yamashita

CEO, Princess Margaret Cancer Centre Foundation
Miyo joined The Princess Margaret Cancer Foundation as its new President and CEO in July 2021. Prior to joining this, Miyo worked in corporate Canada, where she has held senior leadership roles in multiple industries, including management consulting and banking, including Chief Strategy Officer for one of Canada’s largest and fastest growing artificial intelligence startups, MindBridge Ai.  An entrepreneur by background, Miyo founded her own $20million consulting company, which she ran for 8 years before it was acquired by Deloitte Canada in 2010. At Deloitte, Miyo served on the Executive Committee of the Canadian and Chilean firms, where she led the firm’s priority client accounts, the HR function, Marketing, Brand, and the client and employee experience. She also served on Deloitte's global board of directors, the first woman from a minority group in the firm’s 160-year history to do so. In 2017, she was named one of Canada’s Top 100 Most Powerful Women by the Women’s Executive Network.


Cell and Gene Therapies
AI Applications, Digital Health, Data
Product Development Resources
UHN Companies / New Ventures

Event Agenda to come.

illustration of two hands shaking

Accelerator Fund

The Accelerator Fund offers significant capital to help early-stage technologies advance. The fund is designed to expedite the promise of innovations within UHN and partner organizations to get them to patients faster. This fund will help those who need the funding to enhance their commercial potential and bring new medical products, devices, and therapies to the market more swiftly.

Learn More